9
2
3
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T61811 | GPVI antagonist 3 | ||
GPVI antagonist 3 (Compound 2) is a potential antagonist that shows promising antiplatelet activity by selectively inhibiting the interaction between the Glycoprotein VI (GPVI) receptor and its ligands. It demonstrates p... | |||
T62250 | GPVI antagonist 2 | ||
GPVI antagonist 2 (Compound 1) is a potential Glycoprotein VI (GPVI) antagonist, able to act on collagen (IC50: 0.35 μM), CRP (IC50: 0.80 μM), convulxin (IC50: 195.2 μM), thrombin (IC50. 81.38 μM). GPVI antagonist 2 is a... | |||
T61697 | GPVI antagonist 1 | ||
GPVI antagonist 1 (compound 5) functions as an antagonist for the glycoprotein VI (GPVI) platelet receptor. It effectively inhibits collagen-induced platelet aggregation, demonstrating an IC50 value of 25.3 μM [1]. | |||
T0948 | Adrenalone hydrochloride | Adrenalone HCl | Adrenergic Receptor |
Adrenalone hydrochloride (Adrenalone HCl) is a dopamine β-oxidase inhibitor with a similar structure to the norepinephrine transporter (NET) ligand, with an IC50 of 36.9 μM. It is an adrenergic agonist that acts as a loc... | |||
T28281 | OXSI-2 | OXSI 2,Syk Inhibitor | Syk |
OXSI-2 (Syk Inhibitor) is an inhibitor of Syk with an EC50 of 313 nM and an IC50 of 14 nM. OXSI-2 completely inhibits Adaptor protein LAT Y191 phosphorylation and Syk mediated events in platelets. | |||
T77442 | Glenzocimab | ACT017 | Others |
Glenzocimab (ACT017) is a Fab fragment of a humanized anti-GPVI monoclonal antibody. Glenzocimab demonstrated inhibition of collagen-induced platelet aggregation in an ischemic stroke model. Glenzocimab has been studied ... | |||
T11824LL | Lanraplenib | GS-9876 | Syk |
Lanraplenib (GS-9876) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib inhibits SYK activity in platelets via the glycoprotein VI ... | |||
T11824 | Lanraplenib succinate | GS-9876 succinate | Syk |
Lanraplenib succinate inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans. Lanraplenib succinate is a highly selective and orally active S... | |||
T11824L | Lanraplenib monosuccinate | GS-9876 monosuccinate | Syk |
Lanraplenib monosuccinate inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans. Lanraplenib monosuccinate is a highly selective and orally... |
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
TN3460 | Asebogenin | Antifungal | |
Asebogenin is a compound fractionated from Salvia miltiorrhiza with antifungal activity, inhibition of GPVI-induced platelet reactions, and inhibition of NET formation induced by pro-inflammatory stimuli. | |||
T4S0498 | Glaucocalyxin A | Wangzaozin B,Leukamenin F | Apoptosis , Akt , Caspase , PI3K |
1. Glaucocalyxin A (Leukamenin F)-SBE-β-CD could be useful with a better solubility and sustained function in drug delivery. 2. Glaucocalyxin A activates caspase-3, decreases BAD phosphorylation, and reduces the expressi... |
Cat No. | Product Name | Species | Expression System |
---|---|---|---|
TMPK-01302 | GPVI Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 Cells |
Although platelets are best known for their role in hemostasis, they are also crucial in development, host defense, inflammation, and tissue repair. Many of these roles are regulated by the immune-like receptors glycopro... | |||
TMPK-01190 | GPVI Protein, Human, Recombinant (His) | Human | HEK293 Cells |
Although platelets are best known for their role in hemostasis, they are also crucial in development, host defense, inflammation, and tissue repair. Many of these roles are regulated by the immune-like receptors glycopro... | |||
TMPJ-00605 | GPVI Protein, Mouse, Recombinant (His) | Mouse | HEK293 Cells |
Glycoprotein VI (GPVI) is a 63 kDa platelet/megakaryocyte-specific type I transmembrane glycoprotein of the immunoglobulin superfamily that is an important collagen receptor and initiator of platelet activation, aggregat... |